U.S. FDA Clears Takeda Uloric For Gout Indication
This article was originally published in PharmAsia News
Executive Summary
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years